It is the same with Semaglutide
Todays milestone establishes Ozempic as an option for patients to help address two critical aspects of managing type 2 diabetes, blood sugar control and cardiovascular risk reduction, in those with known heart disease. Changes to Rybelsus Prescribing Information The Rybelsus (semaglutide) prescribing information has been updated in section 14 (clinical studies) to include an analysis from the primary endpoint of the PIONEER 6 CVOT showing the hazard ratio for time to first three-component MACE (HR 0.79 [95% CI: 0.57, 1.11]).[5] In June 2019, Novo Nordisk initiated the SOUL CVOT in 9,642 adults with type 2 diabetes and established cardiovascular disease to further evaluate the cardiovascular effect of Rybelsus
The type 2 diabetes section can help place this medicine within the wider treatment area
And population-level observational studies have not identified a signal suggesting increased medullary thyroid carcinoma risk in GLP-1 receptor agonist users
Many participants also showed improvements in blood pressure, cholesterol, and markers of inflammation
Tian H, Chang M, Lyu Y, Dong N, Yu N, Yin T, et al
